Literature DB >> 16954280

Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Michelle Marcial1, Jing Lu, Steven G Deeks, Rainer Ziermann, Daniel R Kuritzkes.   

Abstract

The performance of a gp41 assay, created using reagents designed for use with the OpenGene DNA Sequencing System, was evaluated using a panel of plasma samples obtained from enfuvirtide-naive and -experienced human immunodeficiency virus type 1-infected subjects. Resulting sequence data were highly accurate compared to a "home brew" assay and clonal sequence analysis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16954280      PMCID： PMC1594677          DOI： 10.1128/JCM.00666-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Accuracy of the TRUGENE HIV-1 genotyping kit.

Authors:  Robert M Grant; Daniel R Kuritzkes; Victoria A Johnson; John W Mellors; John L Sullivan; Ronald Swanstrom; Richard T D'Aquila; Mark Van Gorder; Mark Holodniy; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.

Authors:  Prakash R Sista; Tom Melby; Donna Davison; Lei Jin; Sarah Mosier; Mike Mink; Emily L Nelson; Ralph DeMasi; Nick Cammack; Miklos P Salgo; Tom J Matthews; Michael L Greenberg
Journal:  AIDS       Date:  2004-09-03       Impact factor: 4.177

3.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

4.  Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.

Authors:  Daniel R Kuritzkes; Robert M Grant; Paul Feorino; Marshal Griswold; Marie Hoover; Russell Young; Stephen Day; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples.

Authors:  S Cunningham; B Ank; D Lewis; W Lu; M Wantman; J A Dileanis; J B Jackson; P Palumbo; P Krogstad; S H Eshleman
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

8.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.

Authors:  Anne-Geneviève Marcelin; Jacques Reynes; Sabine Yerly; Nadine Ktorza; Michel Segondy; Jean-Claude Piot; Jean-François Delfraissy; Laurent Kaiser; Luc Perrin; Christine Katlama; Vincent Calvez
Journal:  AIDS       Date:  2004-06-18       Impact factor: 4.177
View more
  4 in total

1.  Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Authors:  V A Morozov; A V Morozov; S Lagaye
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

2.  Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.

Authors:  Michael Y K Leung; Fredric S Cohen
Journal:  Biophys J       Date:  2011-04-20       Impact factor: 4.033

Review 3.  HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-03-01       Impact factor: 2.332

4.  Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.

Authors:  Michele Smith; Jonathon Hoffman; Hakimuddin Sojar; Ravikumar Aalinkeel; Chiu-Bin Hsiao; Mark Daniel Hicar
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.